Manufacturers ink deal to make generic version of Pfizer’s oral COVID-19 pill Paxlovid

The Medicines Patent Pool (MPP) announced that it has signed agreements with 35 manufacturers to make an inexpensive version of Pfizer’s (NYSE: PFE) Paxlovid (nirmatrelvir/ritonavir) to be distributed in 95 low- and middle-income countries.

Vaccination rates in many developing countries lag far behind that of wealthier countries. In Nigeria, for instance, 9.1% of the population has received at least one dose, whereas 77% of those in the U.S. are partially or fully vaccinated.

The U.S. pays roughly $530 for a course of Paxlovid.

Pfizer has previously stressed its goal of providing equitable access to COVID-19 therapies worldwide. In November 2021, the company entered a deal with MPP to ensure the availability of Paxlovid to low- and middle-income countries.

“Nirmatrelvir is a new product and requires substantial manufacturing capabilities to produce, and we have been very impressed with the quality of manufacturing demonstrated by these companies,”…

Read more
  • 0

Generic manufacturers to make cheaper version of Merck’s COVID-19 pill for developing countries

Image courtesy of Merck & Co.

The Medicines Patent Pool (MPP) announced today that it signed agreements with 27 manufacturers to produce Merck’s COVID-19 pill.

MPP’s agreements with the generic manufacturing companies cover the manufacturing of the oral COVID-19 antiviral medication molnupiravir, with supply set for 105 low- and middle-income countries (LMICs). The agreements come as a result of the voluntary licensing agreement signed by MPP and MSD, a trade name of Merck, to facilitate the affordable global access of the antiviral drug that MSD is developing in partnership with Ridgeback Biotherapeutics.

Companies offered the sublicenses — which allow generic manufacturers to produce the raw ingredients for molnupiravir and/or the finished drug itself — successfully demonstrated their ability to meet MPP’s requirements related to production capacity, regulatory compliance and t…

Read more
  • 0